Commercialisation Australia closes for new applications
22 May, 2014Commercialisation Australia (CA) is now closed for new applications, following the announcement in last week's federal Budget that it will cease from 1 January 2015 and the funds will be rolled into the new Entrepreneurs' Infrastructure Program (EIP).
Immuron signs SK distribution deal for Travelan
22 May, 2014 by Dylan Bushell-EmblingDB Pharm Korea has signed a deal giving it exclusive rights to distribute Immuron's (ASX:IMC) travellers' diarrhoea treatment Travelan in South Korea.
Phosphagenics' opioid patch eases pain in horses
21 May, 2014 by Dylan Bushell-EmblingAll six injured thoroughbred racehorses treated with Phosphagenics' TPM/oxycodone patch during a pilot trial recovered from pain within 48 hours.
Avita appoints new chairman
20 May, 2014 by Dylan Bushell-EmblingLou Panaccio, an executive with more than 30 years of healthcare and life science experience, has joined the board of Avita Medical (ASX:AVH) as its chairman.
Research Australia Awards 2014 open for nominations
20 May, 2014The Research Australia Awards 2014 are calling for nominations of those making an impact early in their research career; those constantly advocating for health and medical research; philanthropic heroes; and exceptional leaders and pioneers.
Clinuvel gets orphan status for Scenesse in HHD
20 May, 2014 by Dylan Bushell-EmblingClinuvel (ASX:CUV) has received EMA orphan drug designation for Scenesse in Hailey-Hailey Disease, and has revealed it expects the agency to complete its review of the product in EPP by October.
Phylogica hit with two market setbacks
19 May, 2014 by Dylan Bushell-EmblingPhylogica's (ASX:PYC) research partner Janssen Pharmaceuticals has elected not to license the outcome of their collaboration and a Phylogica licensee has filed for bankruptcy.
GI Dynamics' EndoBarrier reduces need for insulin
16 May, 2014 by Dylan Bushell-EmblingGI Dynamics (ASX:GID) said Australian type 2 diabetes patients treated with its EndoBarrier therapy were able to reduce or eliminate insulin therapy.
Bruising Budget strengthens resolve
15 May, 2014The biotech sector is regrouping after the bruising Federal Budget on Tuesday night delivered a round of cuts for biotechnology, including measures to reduce the R&D Tax Incentive and abolish the Innovation Investment Fund (IIF) and Commercialisation Australia (CA).
Clinuvel raises $7.2m for Scenesse development
14 May, 2014 by Dylan Bushell-EmblingClinuvel Pharmaceuticals (ASX:CUV) has closed a $7.2m private placement, to help fund development of Scenesse in vitiligo and a post-marketing study of the drug in EPP.
Dimerix names new director, scientific advisor
13 May, 2014 by Dylan Bushell-EmblingDimerix has hired former Calzada chairman David Franklyn as a non-executive director, and veteran scientist Dr Brian Richardson as part of its scientific advisory team.
CSL opens recombinant therapy plant in Vic
13 May, 2014 by Dylan Bushell-EmblingCSL (ASX:CSL) has opened a biotechnology manufacturing plant in Melbourne as part of a $257m expansion of its Broadmeadows facilities.
Tension high as Federal Budget looms
13 May, 2014Reports of potential reduction of industry-support programs, on the back of the Commission of Audit report, are causing angst in the biotech sector as the industry fears decisions that could seriously damage Australia's hard-won momentum in innovation.
Admedus closes $8m placement
12 May, 2014 by Dylan Bushell-EmblingAdmedus (ASX:AHZ) has raised $8m in a placement, with plans to put the proceeds towards expanding its US and EU reach for CardioCel and to help fund a phase II trial of its HSV-2 vaccine.
3D-printed mouthpiece to treat sleep apnoea
12 May, 2014A new 3D-printed customised mouthpiece is set to provide relief for patients with sleep apnoea.
